Evaxion — AI-designed personalized neoantigen vaccines (EVX-01) on its PIONEER prediction platform.
Evaxion will present three-year clinical efficacy data for its personalized cancer vaccine, EVX-01, at the ESMO Congress 2026. The presentation focuses on long-term outcomes, offering investors insight into the durability of patient responses to this neoantigen-targeted therapy.
17.7.2026 13:15:00 CEST | GlobeNewswire by notified | Press release COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinica…
The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not admini…
Datavault AI Announces Tokenization of Available Infrastructure’s... Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results ... Hyperscale Data Begins Installation of Omnipresent Robotics OPR-R... Faraday Future Showcases Its EAI Robot World Across Three High-Le... Lian…